Nucleic Acid Amplification Testing Market Expected to Reach $9.1 Billion by 2032—Allied Market Research

According to a new report published by Allied Market Research, titled, “Nucleic Acid Amplification Testing Market," The nucleic acid amplification testing market was valued at $4.8 billion in 2022, and is estimated to reach $9.1 billion by 2032, growing at a CAGR of 6.6% from 2023 to 2032. Nucleic acid amplification testing is a molecular diagnostic technique used for detection of various infectious diseases such as HIV, tuberculosis, and cancer, such as cervical cancer. NAAT offers several advantages over the traditional diagnostic techniques, which is one of the major nucleic acid amplification testing market trends.

NAAT is sensitive and detects the target molecule in a small sample. This makes it suitable for the detection of infections at an early stage when the pathogen or mutations are at low rate. In addition, NAAT are highly specific in nature which reduces the chances of false results and helps in accurate diagnosis of the condition. Such advantages offered by NAAT are increasing its demand, which is boosting the nucleic acid amplification testing market share . 

Furthermore, technological advancements in the field of diagnostics propel nucleic acid amplification testing market size. Nucleic acid amplification techniques are transforming the field of bio-detection by opening more options for innovative diagnoses that achieve high efficacy, specificity, and economic viability.

In both research and clinical settings, nucleic acid amplification techniques (NAATs) such as Polymerase Chain Reaction (PCR), Rolling Circle Amplification (RCA), Loop-Mediated Isothermal Amplification (LAMP), Recombinase Polymerase Amplification (RPA), CRISPR-related amplification, and others predominate. Each of them has diverse properties that deliver desired performance in terms of sensitivity, specificity, ease of use, stability, and affordability.  

In addition, automatic systems and robotic platforms have been incorporated into clinical laboratories to streamline NAAT workflows, reduce human error, and increase testing capacity. In addition, the use of innovative bioinformatics tools and software has become a crucial component of NAAT analysis, allowing for the interpretation of large data sets and assisting in the identification of new biomarkers and genetic variations.  

On the basis of technology, the market is segmented into polymerase chain reaction (PCR), and isothermal nucleic acid amplification technology (INAAT) tests. The polymerase chain reaction segment dominated the market in terms of revenue in 2022 and is anticipated to be the fastest growing segment during the forecast period. The growth of the segment is attributed to the significant demand for PCR test kits in the healthcare sector for detection of various infectious diseases. As the incidences of infectious diseases increases, there increase the demand for testing kits based on PCR technology, which contributes to the growth of nucleic acid amplification testing market share.  

In addition, the PRC technique offers several advantages such as it allows detection of pathogens, which are difficult to culture invitro or which require lengthy culture procedures. In addition to being an excellent screening method, PCR is particularly effective in finding cases in extra pulmonary specimens that go undetected by smear. This boosts the adoption of PCR technique for disease diagnosis which contributes to the segment revenue generation.  

On the basis of application, the market is segmented into infectious diseases testing, oncology testing and others. The infectious disease testing segment dominated the market in 2022 in terms of revenue and is anticipated to be the fastest growing segment during the forecast period. This growth of the segment is attributed to the rising incidences of infectious diseases and certain pandemics and outbreaks, which increase the demand for nucleic acid amplification testing for efficient diagnosis of the infection. In addition, LAMP, and SDA, offer rapid and highly specific detection of infectious pathogens such as tuberculosis and viruses. This rapid detection of infectious diseases further contributes toward the nucleic acid amplification testing market size . 

On the basis of end user, the market is segmented into hospital-based laboratories, central, reference & standalone laboratories and others. The central, reference and standalone laboratories dominated the market in 2022 in terms of revenue. This growth is mainly attributed to the availability of highly specialized and skilled staff who are well trained in performing NAAT. This expertise ensures the accuracy and reliability of test results, making it a preferred choice for many healthcare providers.  

On the other hand, the hospitals-based laboratories segment is anticipated to be the fastest growing segment during the nucleic acid amplification testing market forecast period, owing to the adoption of highly advanced diagnostic systems and technologies in the hospitals and surge in number for diagnostic testing in the hospitals. 

On the basis of region, nucleic acid amplification testing market analysis is done accross North America, Europe, Asia-Pacific and LAMEA. North America held the largest share of the market in terms of revenue in 2022. This growth is attributed to the well-developed healthcare infrastructure in this region and awareness among people regarding advanced molecular diagnostic techniques. On the other hand, the Asia-pacific region is anticipated to be the fastest growing segment during the forecast period, owing to high incidence of infectious diseases, high prevalence of cancer and government support for early diagnosis and treatment of diseases. 

 Key findings of the study  

• By technology, the polymerase chain reaction (PCR) tests segment was the highest contributor to the nucleic acid amplification testing industry in 2022.  

• By application, the infectious disease testing segment was the highest contributor to the market in 2022 in terms of revenue.  

• By end user, the central, reference and standalone laboratories segment dominated the market in terms of revenue in 2022.  

• Region wise, North America generated the largest revenue in 2022 in nucleic acid amplification testing industry, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.